Trials
3 active
7 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned…”In the company’s words, NCT03846219 on ClinicalTrials.gov
- Tested for
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis (RRMS)
- Main trialPhase 3
- “Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)”In the company’s words, NCT05134441 on ClinicalTrials.gov
- Other names
- IM90838 · vidofludimus calcium
Other drugs for Multiple Sclerosis
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
- BCD-281Biocad · Phase 3
Coming up2
- NovPhase 3 trial completes · ClinicalTrials.gov
- NovPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2026 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | |
| Phase 3Active, not recruiting | Nov 2026 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | |
| Phase 2Active, not recruiting | 24 Apr 2020 | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) | |
| Phase 2/3Completed | 12 Jan 2021 | A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) | |
| Phase 2Terminated | 16 Nov 2022 | Phase 2 Dose-finding IMU-838 for Ulcerative Colitis | |
| Phase 2Unknown | 7 Jan 2025 | Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis | |
| Phase 2Ended | not given | Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026